tag:blogger.com,1999:blog-16774010.post7930459163120556503..comments2024-01-25T17:58:34.297-05:00Comments on Scott's Web Log: The Business of Diabetes: Recent Comments from Wall StreetScott Shttp://www.blogger.com/profile/03286529314567223617noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-16774010.post-90505505214958854112006-12-16T13:12:00.000-05:002006-12-16T13:12:00.000-05:00Yes, you read correctly (at least according to Wal...Yes, you read correctly (at least according to Wall Street analysts). Novo already has more salespeople, which is why Lilly felt the need to boost its salesforce by another 40%!<br /><br />This is part of a big problem in the pharmaceutical industry -- they now spend more on marketing than they do on research (at least that's the case with Pfizer) and most doctors complain they simply do not have time to see all of these salespeople. The salespeople are not getting the welcome they once did, and doctors are telling them that THEY will call when they want to speak with a pharmaceutical salesperson.<br /><br />I don't think this can continue like this forever!Scott Shttps://www.blogger.com/profile/03286529314567223617noreply@blogger.comtag:blogger.com,1999:blog-16774010.post-37133529669781714202006-12-16T02:32:00.000-05:002006-12-16T02:32:00.000-05:00Did I read correctly that Novo is looking to add 8...Did I read correctly that Novo is looking to add 800 (!?) sales reps! Cripes! That sounds like a lot...<br /><br />Great summary - once again I'm grateful for your knack of clearly updating us on these types of things.Scott K. Johnsonhttps://www.blogger.com/profile/06601851114190791084noreply@blogger.com